Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin (2024)
RGD-decorated liposome / dipalmitoyl-GRGDSPA
Sequence: GRGDSPA
| Experiment Id | EXP002454 |
|---|---|
| Paper | Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin |
| Peptide | RGD-decorated liposome / dipalmitoyl-GRGDSPA |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | not separately specified; RGD-modified liposome dose based on cargo dosing |
| Rna Concentration | 1.5 mg/kg miR-34a with 10 mg/kg cisplatin; repeated every 72 h for 12 days |
| Mixing Ratio | Lipid composition DSPC:cholesterol:dipalmitoyl-GRGDSPA = 7:3:1 mM; protamine/miR-34a complex formed before liposome hydration |
| Formulation Format | RGD-modified liposome co-delivering cisplatin and protamine-complexed miR-34a |
| Formulation Components | DSPC, cholesterol, dipalmitoyl-GRGDSPA, protamine, miR-34a, cisplatin |
| Size Nm | 213.90 |
| Zeta Mv | -10.70 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice bearing subcutaneous 4T1 breast tumors |
| Administration Route | repeated injections every 72 h for 12 days; exact route not specified in the uploaded main text |
| Output Type | tumor growth inhibition / tumor regression |
| Output Value | Tumor volume after 21 days: Cis-miR34a 9 mm2, Cis-miR34a-Lip 6.25 mm2, Cis-miR34a-Lip-RGD 2.10 mm2 |
| Output Units | |
| Output Notes | In vivo functional antitumor outcome demonstrated for the peptide-decorated RNA-containing formulation; improvement attributed to RGD-mediated targeted delivery. |
| Toxicity Notes | Mouse body weight did not show major adverse loss; the authors state weight maintenance supports safety of the delivery system for vital organs. |
| Curation Notes |